China Pharmaceutical Holdings Restricted (NYSE American: CPHI) (“China Pharma” or “Firm”), an NYSE American-listed company with a totally-built-in specialty prescription drugs subsidiary based mostly in China, at the moment introduced that its subsidiary, Hainan Helpson Pharmaceutical & Biotechnology Co., Ltd. (“Helpson”) launched masks manufacturing traces.
The masks are produced in Class 100,000 Clear Room (air cleanliness class refers back to the classification standards for classification by most focus limits of particles which might be higher than or equal to the particle sizes into consideration within the Clear Room) by our subsidiary, Helpson, a cGMP licensed pharmaceutical producer, which ensures security and well being.
Ms. Li Zhilin, President and CEO of China Pharmaceutical mentioned, “On the one hand, though the COVID-19 outbreak has been managed to a sure extent in China at the moment; the federal government and the general public’s consciousness of epidemic prevention remains to be robust. And actions comparable to work resumption and faculties re-open create a excessive demand for protecting masks. Alternatively, the worldwide outbreak of COVID-19 has led to a surge in demand for protecting tools resembling masks. On this circumstance, we take the time to launch masks manufacturing strains, adhering to our company mission of offering primary medical safety measures to most of the people, and fulfilling our social duty with sensible actions. “
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical firm that develops, manufactures and markets a diversified portfolio of merchandise, specializing in situations with excessive incidence and excessive mortality charges in China, together with cardiovascular, CNS, infectious, and digestive ailments. The Firm’s price-efficient enterprise mannequin is pushed by market demand and supported by new GMP-licensed product traces overlaying the most important dosage types. As well as, the Firm has a broad and increasing nationwide distribution community throughout all main cities and provinces in China. The Firm’s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is situated in Haikou Metropolis, Hainan Province.
Protected Harbor Assertion
Sure statements on this press launch represent ahead-wanting statements for functions of the secure harbor provisions below The Personal Securities Litigation Reform Act of 1995. Any statements set forth above that aren’t historic information are ahead-trying statements that contain dangers and uncertainties that might trigger precise outcomes to vary materially from these within the ahead-wanting statements. Such dangers and uncertainties could embrace, however usually are not restricted to: the achievability of monetary steering; success of latest product growth; unanticipated modifications in product demand; elevated competitors; downturns within the Chinese language economic system; uncompetitive ranges of analysis and improvement; and different data detailed infrequently within the Firm’s filings and future filings with america Securities and Change Fee. The ahead-trying statements made herein communicate solely as of the date of this press launch and the Firm undertakes no responsibility to replace any ahead-trying assertion to evolve the assertion to precise outcomes or modifications within the Firm’s expectations, besides as required by relevant regulation or laws.